Lung function and serum concentration of tumor necrosis factor-alpha, interleukin-6 and fibronectin in patients treated with ABVD chemotherapy followed by radiotherapy for mediastinal Hodgkin's disease.
Mediastinal radiotherapy and polychemotherapy regimens can produce late toxicity leading to pulmonary fibrosis. There is evidence for the involvement of various cytokines in this process. We evaluated lung function in 20 patients with stage I-IIA Hodgkin's disease and submitted to chemotherapy including bleomycin (ABVD) and radiotherapy. Lung function tests were performed before, at the end of treatment and after a median of 12 months from the end of therapy. Tumor necrosis factor-alpha (TNF-alpha), fibronectin and interleukin-6 (IL-6) were determined on serum samples collected at the same time intervals. A modification of tests indicative of a restrictive lung disease was observed at end of treatment, whereas a persistent decline of transfer lung factor for carbon monoxide (DLCO) was documented. TNF-alpha constantly decreased, fibronectin increased and IL-6 showed a decline after treatment and a rise during the follow-up but the differences were not statistically significant. No significant correlations were observed between changes of lung function tests and serum cytokine concentration.


CONCLUSIONS
This lack of correlation could be due to: a) incorrect selection of serum collection time, or b) to the fact that cytokine plasma concentration does not reflect events occurring in the alveolar phase.
Villani
F
F
Divisione di Cardiologia e Fisiopatologia Respiratoria, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.
Dell'Oca
I
I
De Maria
P
P
Viola
G
G
Di Russo
A
A
Viviani
S
S
Bonfante
V
V
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005353:Fibronectins / Q000097:blood*; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology* / Q000532:radiotherapy; D006801:Humans; D015850:Interleukin-6 / Q000097:blood*; D008297:Male; D008479:Mediastinal Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology* / Q000532:radiotherapy; D008875:Middle Aged; D012129:Respiratory Function Tests; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis*; D014747:Vinblastine / Q000627:therapeutic use
D005353:Fibronectins; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D001761:Bleomycin; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin